John Oyler Sells 48,520 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 48,520 shares of BeOne Medicines stock in a transaction dated Monday, July 13th. The stock was sold at an average price of $304.35, for a total transaction of $14,767,062.00. Following the sale, the chief executive officer directly owned 11,698 shares of the company’s stock, valued at $3,560,286.30. The trade was a 80.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John Oyler also recently made the following trade(s):

• On Friday, July 10th, John Oyler sold 11,698 shares of BeOne Medicines stock. The shares were sold at an average price of $298.34, for a total transaction of $3,489,981.32.
• On Tuesday, July 14th, John Oyler sold 145,861 shares of BeOne Medicines stock. The stock was sold at an average price of $305.95, for a total transaction of $44,626,172.95.
• On Tuesday, June 23rd, John Oyler sold 3,410 shares of BeOne Medicines stock. The stock was sold at an average price of $273.78, for a total value of $933,589.80.
• On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The shares were sold at an average price of $265.55, for a total value of $980,676.15.
• On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The stock was sold at an average price of $257.24, for a total value of $501,360.76.
• On Monday, June 8th, John Oyler sold 4,940 shares of BeOne Medicines stock. The stock was sold at an average price of $270.56, for a total value of $1,336,566.40.

BeOne Medicines Stock Performance

ONC opened at $311.26 on Thursday. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. The business has a fifty day simple moving average of $290.20 and a 200 day simple moving average of $308.90. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $253.95 and a 1 year high of $385.22. The company has a market capitalization of $34.15 billion, a PE ratio of 69.63 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last announced its earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The company had revenue of $1.51 billion during the quarter. Research analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 5.86 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Morgan Stanley reiterated an “overweight” rating and issued a $395.00 price target on shares of BeOne Medicines in a research report on Thursday, May 7th. Truist Financial raised their price objective on BeOne Medicines from $413.00 to $416.00 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. Wall Street Zen cut BeOne Medicines from a “strong-buy” rating to a “buy” rating in a report on Monday, July 6th. Zacks Research downgraded BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 3rd. Finally, Leerink Partners raised their price target on BeOne Medicines from $364.00 to $367.00 and gave the stock an “outperform” rating in a research report on Friday, May 15th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $390.92.

Hedge Funds Weigh In On BeOne Medicines

A number of institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets boosted its position in BeOne Medicines by 100.6% in the fourth quarter. BNP Paribas Financial Markets now owns 193,951 shares of the company’s stock valued at $58,924,000 after buying an additional 97,244 shares in the last quarter. Capital International Sarl lifted its stake in shares of BeOne Medicines by 2.7% in the 4th quarter. Capital International Sarl now owns 152,515 shares of the company’s stock valued at $46,336,000 after acquiring an additional 3,956 shares during the last quarter. Slow Capital Inc. boosted its holdings in shares of BeOne Medicines by 51.5% during the 4th quarter. Slow Capital Inc. now owns 27,301 shares of the company’s stock valued at $8,294,000 after acquiring an additional 9,280 shares in the last quarter. Capital International Investors boosted its holdings in shares of BeOne Medicines by 1.3% during the 4th quarter. Capital International Investors now owns 5,113,866 shares of the company’s stock valued at $1,553,909,000 after acquiring an additional 67,808 shares in the last quarter. Finally, AIA Group Ltd grew its position in BeOne Medicines by 31.4% during the 3rd quarter. AIA Group Ltd now owns 32,303 shares of the company’s stock worth $11,006,000 after acquiring an additional 7,716 shares during the last quarter. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.